Worth reading
45Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-3871
¥ million (year-on-year change in revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsThird quarter of the fiscal year ending May 20267 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥17,346 million-18.2%
Operating profit¥-899 million
Ordinary income¥9 million
Net income¥-240 million
Selling, general and administrative expenses¥4,935 million
Operating profit marginCumulative 3Q: ▲5.2%; ▲8.6 percentage points year on year
Results for the three months of the current quarter
Net Sales
¥6,211 million
Gross profit
¥1,438 million
Selling, general and administrative expenses
¥1,678 million
Operating profit
¥-239 million
Ordinary income
¥-107 million
Profit attributable to owners of parent for the quarter
¥-234 million
Full-year earnings forecast
Net Sales
¥24,119 million
Operating profit
¥-814 million
Ordinary income
¥47 million
Profit attributable to owners of the parent
¥30 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Net Sales
Japan-3,822
Asia-142
North America132
Europe-364
Foreign Exchange Effects326
Operating profit
Change in COSEL product revenue-1,801
Change in PRBX product revenue70
PRBX product cost ratio-150
COSEL product variable cost ratio105
Personnel Expenses-8
Depreciation and amortization-7
Expenses162
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
In 4Q, adjustments to advance orders from medical and communications equipment manufacturers are expected. Orders are expected to remain firm, based on customer inventory digestion and increased demand related to semiconductor manufacturing equipment. Numerical assumptions: Not disclosed.Key KPIsA metric the company considers important as a management benchmark.
- Orders received77.1 Hundreds of millions of yen
- Bill-to-book ratio1.24 times
- Overseas revenue ratio41.5 %
- Equity ratio91.7 %
- USD/JPY¥150.03
Financial targets
Equity ratio: 91.7% (actual for 3Q of the fiscal year ending May 2026); target: Not disclosedOrders received and order backlog
Orders received77.1 Hundreds of millions of yen
Capital expenditures
¥980 million FY2025 forecast
Annual Dividend
Annual¥55 per share
Interim¥27 per share
End of period¥28 per share
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Third quarter of the fiscal year ending May 2026 |
| Net Sales | ¥17,346 million (YoY -18.2%) |
| Operating profit | ¥-899 million |
| Ordinary income | ¥9 million |
| Net income | ¥-240 million |
| Operating profit margin | Cumulative 3Q: ▲5.2%; ▲8.6 percentage points year on year |
| Selling, general and administrative expenses | ¥4,935 million |
| Results for the three months of the current quarter | Net Sales ¥6,211 million / Gross profit ¥1,438 million / Selling, general and administrative expenses ¥1,678 million / Operating profit ¥-239 million / Ordinary income ¥-107 million / Profit attributable to owners of parent for the quarter ¥-234 million |
| Full-year earnings forecast | Net Sales ¥24,119 million / Operating profit ¥-814 million / Ordinary income ¥47 million / Profit attributable to owners of the parent ¥30 million |
| Breakdown of Factors Affecting the Change | Net Sales Japan -3,822 / Asia -142 / North America 132 / Europe -364 / Foreign Exchange Effects 326 / Operating profit Change in COSEL product revenue -1,801 / Change in PRBX product revenue 70 / PRBX product cost ratio -150 / COSEL product variable cost ratio 105 / Personnel Expenses -8 / Depreciation and amortization -7 / Expenses 162 |
| Key KPIs | Indicator name Orders received / Value 77.1 Hundreds of millions of yen / Year on year against the same period last year Not disclosed, Indicator name Bill-to-book ratio / Value 1.24 times / Year on year against the same period last year Not disclosed, Indicator name Overseas revenue ratio / Value 41.5 % / Year on year against the same period last year Not disclosed, Indicator name Equity ratio / Value 91.7 % / Year on year against the same period last year Not disclosed, Indicator name USD/JPY / Value ¥150.03 / Year on year against the same period last year Not disclosed |
| Assumptions Underlying the Business Outlook | In 4Q, adjustments to advance orders from medical and communications equipment manufacturers are expected. Orders are expected to remain firm, based on customer inventory digestion and increased demand related to semiconductor manufacturing equipment. Numerical assumptions: Not disclosed. |
| Financial targets | Equity ratio: 91.7% (actual for 3Q of the fiscal year ending May 2026); target: Not disclosed |
| Annual Dividend | Annual ¥55 per share / Interim ¥27 per share / End of period ¥28 per share |
| Capital expenditures | ¥980 million (FY2025 forecast) |
| Orders received and order backlog | Orders received 77.1 Hundreds of millions of yen / Order backlog Not disclosed |
Items this document does not state (14)
Gross Profit MarginProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsPayout ratioAcquisition of treasury sharesMarket Size / ShareKey points of the Q&ANew initiatives
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The substantial decline in revenue prevented fixed costs from being absorbed, resulting in lower operating income. Revenue was weaker year on year in Japan, Asia, North America and Europe, while demand adjustments and customer order adjustments continued in Europe.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.